Clinical Trial Update: Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituximab for severe ocular manifestations of Behçet's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Behcet's Syndrome | Phase 2 | Status: COMPLETED